Form 8-K · Current Report · Filed 2026-08-04
Amgen Reports Strong Second Quarter 2026 Financial Results and Product Performance
Amgen Inc. reported strong financial results for the second quarter of 2026, with total revenues increasing by 10% to $10.1 billion. GAAP earnings per share (EPS) increased by 65% to $4.37, driven by higher revenues. Non-GAAP EPS increased by 4% to $6.29. Product sales grew by 9%, with 22 products delivering at least double-digit sales growth. Key products like Repatha, EVENITY, and TEZSPIRE saw significant growth. The company also provided updates on its pipeline, including Phase 3 studies for MariTide and other products. Free cash flow increased to $3.5 billion, and the company maintained a strong balance sheet with $14.0 billion in cash and cash equivalents.
- Filer
- Amgen Inc. AMGN · NASDAQ
- Filed
- Accession
- 0000318154-26-000124
- CIK
- 0000318154
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$385.16
Since filing
+0.0%
Latest close
$385.16
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from AMGN reporting the same item, with the next session's move:
About Amgen Inc.
Amgen Inc. is a leading biotechnology company focused on the discovery, development, manufacturing, and marketing of human therapeutics. Established in 1980 and headquartered in Thousand Oaks, California, Amgen is recognized for pioneering biologic treatments and having a robust pipeline that targets critical areas like oncology, cardiovascular, and nephrology. The company has harnessed advanced technology platforms and deep scientific expertise to deliver innovative medicines such as Neulasta, Enbrel, and Prolia, which are significant players in the health care sector. Amgen serves markets globally, impacting the biotech industry by transforming the ways diseases are treated. Its investment in state-of-the-art manufacturing facilities and research makes it a significant entity in the pharmaceutical landscape, contributing to long-term health care solutions.
Never miss another AMGN filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.